Safety and Pharmacokinetics of Fluzoparib in Healthy Subjects and Those With Impaired Kidney Function
Status:
Not yet recruiting
Trial end date:
2022-10-28
Target enrollment:
Participant gender:
Summary
The primary objective is to evaluate pharmacokinetics of Fluzoparib and its main metabolite
in subjects with impaired kidney function in comparison with healthy subjects, to develop
dose recommendations for patients with renal impairment.
The secondary objective is to evaluate the safety of Fluzoparib in subjects with mild and
moderate renal impairment and in healthy subjects.